{"transactions":[{"id":4620998,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-09-17T20:05:30.000Z","date":"2026-09-15","kind":"grant","planned":false,"acquired":true,"shares":3694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":327549,"source":{"system":"sec-edgar","filing":"0001193125-26-394323","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000119312526394323/ownership.xml","form_type":"4"}},{"id":733956,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-17T20:42:25.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":63481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":323855,"source":{"system":"sec-edgar","filing":"0001193125-26-274279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000119312526274279/ownership.xml","form_type":"4"}},{"id":733955,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-17T20:42:25.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":4065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":260374,"source":{"system":"sec-edgar","filing":"0001193125-26-274279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000119312526274279/ownership.xml","form_type":"4"}},{"id":837730,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-03-18T00:34:48.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":5800,"price":3.31,"value":19198.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":9188635,"source":{"system":"sec-edgar","filing":"0001193125-26-111581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000119312526111581/ownership.xml","form_type":"4"}},{"id":837729,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-03-18T00:34:48.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":6725000,"price":3.05,"value":20511250.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":9194435,"source":{"system":"sec-edgar","filing":"0001193125-26-111581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000119312526111581/ownership.xml","form_type":"4"}},{"id":837728,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-03-18T00:34:48.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":4451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":256309,"source":{"system":"sec-edgar","filing":"0001193125-26-111581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000119312526111581/ownership.xml","form_type":"4"}},{"id":964867,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-12-17T21:05:07.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":4178,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":251858,"source":{"system":"sec-edgar","filing":"0001193125-25-322690","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000119312525322690/ownership.xml","form_type":"4"}},{"id":1037678,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-09-18T00:28:54.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":11718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":247680,"source":{"system":"sec-edgar","filing":"0001193125-25-206547","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000119312525206547/ownership.xml","form_type":"4"}},{"id":1107855,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-17T20:05:10.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":24193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":235962,"source":{"system":"sec-edgar","filing":"0000950170-25-087350","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017025087350/ownership.xml","form_type":"4"}},{"id":1113219,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-12T20:17:24.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":211769,"source":{"system":"sec-edgar","filing":"0000950170-25-085378","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017025085378/ownership.xml","form_type":"4"}},{"id":1177565,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-04-04T20:05:07.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":10416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":166769,"source":{"system":"sec-edgar","filing":"0000950170-25-051106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017025051106/ownership.xml","form_type":"4"}},{"id":1220408,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2025-03-07T02:30:18.000Z","date":"2025-03-06","kind":"sale","planned":false,"acquired":false,"shares":1196746,"price":17.5177,"value":20964237.4042,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 6, 2025, the Reporting Persons sold 1,196,746 shares of Common Stock at a weighted average price of $17.5177 per share. The shares were sold in multiple open market transactions at prices ranging from $17.48 to $17.64 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":5658705,"source":{"system":"sec-edgar","filing":"0000899140-25-000405","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914025000405/form4.xml","form_type":"4"}},{"id":1220407,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2025-03-07T02:30:18.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":270374,"price":17.6279,"value":4766125.8346,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 5, 2025, the Reporting Persons sold 270,374 shares of Common Stock at a weighted average price of $17.6279 per share. The shares were sold in multiple open market transactions at prices ranging from $17.49 to $17.72 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":6855451,"source":{"system":"sec-edgar","filing":"0000899140-25-000405","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914025000405/form4.xml","form_type":"4"}},{"id":1220406,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2025-03-07T02:30:18.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":151175,"price":17.6291,"value":2665079.1925,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2025, the Reporting Persons sold 151,175 shares of Common Stock at a weighted average price of $17.6291 per share. The shares were sold in multiple open market transactions at prices ranging from $17.55 to $17.89 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":7125825,"source":{"system":"sec-edgar","filing":"0000899140-25-000405","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914025000405/form4.xml","form_type":"4"}},{"id":1326549,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-12-18T21:05:02.000Z","date":"2024-12-16","kind":"grant","planned":false,"acquired":true,"shares":4249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":156353,"source":{"system":"sec-edgar","filing":"0000950170-24-137870","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017024137870/ownership.xml","form_type":"4"}},{"id":1403499,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-18T20:05:08.000Z","date":"2024-09-16","kind":"grant","planned":false,"acquired":true,"shares":3282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":152104,"source":{"system":"sec-edgar","filing":"0000950170-24-107770","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017024107770/ownership.xml","form_type":"4"}},{"id":1471948,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-21T20:05:04.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":24311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":148822,"source":{"system":"sec-edgar","filing":"0000950170-24-076216","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017024076216/ownership.xml","form_type":"4"}},{"id":1475104,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-18T20:05:03.000Z","date":"2024-06-15","kind":"grant","planned":false,"acquired":true,"shares":2572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":124511,"source":{"system":"sec-edgar","filing":"0000950170-24-074833","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017024074833/ownership.xml","form_type":"4"}},{"id":1568337,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-19T20:05:25.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":1662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024."}],"balance_after":121939,"source":{"system":"sec-edgar","filing":"0000950170-24-033454","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017024033454/ownership.xml","form_type":"4"}},{"id":1704729,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-12-19T21:05:26.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":1347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023."}],"balance_after":120277,"source":{"system":"sec-edgar","filing":"0001209191-23-059112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919123059112/doc4.xml","form_type":"4"}},{"id":1777230,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-09-19T21:04:07.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":1798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023."}],"balance_after":118930,"source":{"system":"sec-edgar","filing":"0001209191-23-049996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919123049996/doc4.xml","form_type":"4"}},{"id":1846425,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-22T21:26:48.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":117132,"source":{"system":"sec-edgar","filing":"0001209191-23-039133","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919123039133/doc4.xml","form_type":"4"}},{"id":1850388,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-06-21T01:00:25.000Z","date":"2023-06-15","kind":"purchase","planned":false,"acquired":true,"shares":62000,"price":13.1322,"value":814196.4,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 15, 2023, the Reporting Persons acquired 62,000 shares of Common Stock at a weighted average price of $13.1322 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.075 to $13.18 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":7277000,"source":{"system":"sec-edgar","filing":"0000899140-23-000758","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000758/form4.xml","form_type":"4"}},{"id":1849412,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-20T20:05:25.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":1359,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023."}],"balance_after":94782,"source":{"system":"sec-edgar","filing":"0001209191-23-038339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919123038339/doc4.xml","form_type":"4"}},{"id":1864296,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-06-08T00:10:19.000Z","date":"2023-06-06","kind":"purchase","planned":false,"acquired":true,"shares":8000,"price":13.048,"value":104384.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 6, 2023, the Reporting Persons acquired 8,000 shares of Common Stock at a weighted average price of $13.048 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.04 to $13.09 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":7215000,"source":{"system":"sec-edgar","filing":"0000899140-23-000730","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000730/form4.xml","form_type":"4"}},{"id":1864295,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-06-08T00:10:19.000Z","date":"2023-06-05","kind":"purchase","planned":false,"acquired":true,"shares":7000,"price":13.0424,"value":91296.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 5, 2023, the Reporting Persons acquired 7,000 shares of Common Stock at a weighted average price of $13.0424 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.005 to $13.20 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":7207000,"source":{"system":"sec-edgar","filing":"0000899140-23-000730","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000730/form4.xml","form_type":"4"}},{"id":1875304,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-05-30T23:01:04.000Z","date":"2023-05-30","kind":"purchase","planned":false,"acquired":true,"shares":120000,"price":13.0054,"value":1560648.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 30, 2023, the Reporting Persons acquired 120,000 shares of Common Stock at a weighted average price of $13.0054 per share. The shares were purchased in multiple open market transactions at prices ranging from $12.93 to $13.125 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":7200000,"source":{"system":"sec-edgar","filing":"0000899140-23-000696","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000696/form4.xml","form_type":"4"}},{"id":1875303,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-05-30T23:01:04.000Z","date":"2023-05-26","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":13.1243,"value":393729.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 26, 2023, the Reporting Persons acquired 30,000 shares of Common Stock at a weighted average price of $13.1243 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.011 to $13.14 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":7080000,"source":{"system":"sec-edgar","filing":"0000899140-23-000696","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000696/form4.xml","form_type":"4"}},{"id":1875302,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-05-30T23:01:04.000Z","date":"2023-05-25","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":13.0866,"value":654330.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 25, 2023, the Reporting Persons acquired 50,000 shares of Common Stock at a weighted average price of $13.0866 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.015 to $13.14 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":7050000,"source":{"system":"sec-edgar","filing":"0000899140-23-000696","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000696/form4.xml","form_type":"4"}},{"id":1885508,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-05-20T01:12:19.000Z","date":"2023-05-19","kind":"purchase","planned":false,"acquired":true,"shares":36000,"price":13.4763,"value":485146.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 19, 2023, the Reporting Persons acquired 36,000 shares of Common Stock at a weighted average price of $13.4763 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.47 to $13.49 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein"}],"balance_after":7000000,"source":{"system":"sec-edgar","filing":"0000899140-23-000672","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000672/form4.xml","form_type":"4/A","original_submission_date":"2023-05-19"}},{"id":1885507,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-05-20T01:12:19.000Z","date":"2023-05-18","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":13.0538,"value":130538.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 18, 2023, the Reporting Persons acquired 10,000 shares of Common Stock at a weighted average price of $13.0538 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.01 to $13.07 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein"}],"balance_after":6964000,"source":{"system":"sec-edgar","filing":"0000899140-23-000672","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000672/form4.xml","form_type":"4/A","original_submission_date":"2023-05-19"}},{"id":1885506,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-05-20T01:12:19.000Z","date":"2023-05-17","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":13.0738,"value":653690.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2023, the Reporting Persons acquired 50,000 shares of Common Stock at a weighted average price of $13.0738 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.00 to $13.13 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein"}],"balance_after":6954000,"source":{"system":"sec-edgar","filing":"0000899140-23-000672","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000672/form4.xml","form_type":"4/A","original_submission_date":"2023-05-19"}},{"id":1885505,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-05-20T00:00:27.000Z","date":"2023-05-18","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":13.0538,"value":130538.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 18, 2023, the Reporting Persons acquired 10,000 shares of Common Stock at a weighted average price of $13.0538 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.01 to $13.07 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein"}],"balance_after":6964000,"source":{"system":"sec-edgar","filing":"0000899140-23-000667","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000667/form4.xml","form_type":"4"}},{"id":1885504,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-05-20T00:00:27.000Z","date":"2023-05-17","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":13.0738,"value":653690.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2023, the Reporting Persons acquired 50,000 shares of Common Stock at a weighted average price of $13.0738 per share. The shares were purchased in multiple open market transactions at prices ranging from $13.00 to $13.13 per share, inclusive.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein"}],"balance_after":6954000,"source":{"system":"sec-edgar","filing":"0000899140-23-000667","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000667/form4.xml","form_type":"4"}},{"id":1893982,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"ten_percent_owner":true}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-05-16T01:09:44.000Z","date":"2023-05-11","kind":"purchase","planned":false,"acquired":true,"shares":290000,"price":12.3359,"value":3577411.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 11, 2023, the Reporting Persons acquired 290,000 shares of Common Stock at a weighted average price of $12.3359 per share. The shares were purchased in multiple open market transactions at prices ranging from $12.25 to $12.43.  The Reporting Persons undertake to provide, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to Sarissa Capital Offshore Master Fund LP, Sarissa Capital Catapult Fund LLC, Sarissa Capital Hawkeye Fund LP and Sarissa Capital Master Fund II LP (collectively, the \"Sarissa Funds\") and may be deemed to beneficially own the shares of Common Stock directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the shares of Common Stock. Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer and ultimate general partner of Sarissa Capital and is the ultimate general partner, or controls the managing member, of each of the Sarissa Funds; accordingly, Dr. Denner may be deemed to beneficially own the shares of Common Stock directly held by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Dr. Denner, Sarissa Capital and each of the Sarissa Funds disclaims beneficial ownership of the shares of Common Stock reported herein except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":6904000,"source":{"system":"sec-edgar","filing":"0000899140-23-000656","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914023000656/form4.xml","form_type":"4"}},{"id":1946767,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-17T20:05:11.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":1438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023."}],"balance_after":93423,"source":{"system":"sec-edgar","filing":"0001209191-23-019596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919123019596/doc4.xml","form_type":"4"}},{"id":2081489,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-12-19T21:14:13.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":1244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Policy, effective May 2019."}],"balance_after":91985,"source":{"system":"sec-edgar","filing":"0001209191-22-061864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919122061864/doc4.xml","form_type":"4"}},{"id":2155492,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-09-19T20:05:19.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":1374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Policy, effective May 2019."}],"balance_after":90741,"source":{"system":"sec-edgar","filing":"0001209191-22-050483","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919122050483/doc4.xml","form_type":"4"}},{"id":2227536,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-06-18T00:11:17.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":1222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Policy, effective May 2019."}],"balance_after":89367,"source":{"system":"sec-edgar","filing":"0001209191-22-038192","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919122038192/doc4.xml","form_type":"4"}},{"id":2228917,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-17T20:29:01.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":1370,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15099,"source":{"system":"sec-edgar","filing":"0001127602-22-017773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760222017773/form4.xml","form_type":"4"}},{"id":2244469,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-06-03T20:05:54.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":21571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":88145,"source":{"system":"sec-edgar","filing":"0001209191-22-033974","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919122033974/doc4.xml","form_type":"4"}},{"id":2327163,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-03-17T20:06:23.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":1152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Policy, effective May 2019."}],"balance_after":66574,"source":{"system":"sec-edgar","filing":"0001209191-22-019537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919122019537/doc4.xml","form_type":"4"}},{"id":2465868,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-17T21:07:28.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":1211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Policy, effective May 2019."}],"balance_after":65422,"source":{"system":"sec-edgar","filing":"0001209191-21-070237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919121070237/doc4.xml","form_type":"4"}},{"id":2565617,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-09-17T20:46:22.000Z","date":"2021-09-15","kind":"grant","acquired":true,"shares":1137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Policy, effective May 2019."}],"balance_after":64211,"source":{"system":"sec-edgar","filing":"0001209191-21-056654","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919121056654/doc4.xml","form_type":"4"}},{"id":2646243,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-02T21:35:33.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":775,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13729,"source":{"system":"sec-edgar","filing":"0001127602-21-021352","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760221021352/form4.xml","form_type":"4"}},{"id":2666174,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-06-16T20:30:40.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":1229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Policy, effective May 2019."}],"balance_after":63074,"source":{"system":"sec-edgar","filing":"0001209191-21-040919","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919121040919/doc4.xml","form_type":"4"}},{"id":2680848,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-06-04T20:05:31.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":22766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":61845,"source":{"system":"sec-edgar","filing":"0001209191-21-038186","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919121038186/doc4.xml","form_type":"4"}},{"id":2782013,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-03-17T20:08:48.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":1235,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Policy, effective May 2019."}],"balance_after":39079,"source":{"system":"sec-edgar","filing":"0001209191-21-021307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919121021307/doc4.xml","form_type":"4"}},{"id":2796803,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-03-11T00:06:57.000Z","date":"2021-03-10","kind":"purchase","acquired":true,"shares":75000,"price":10.54,"value":790500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of Sarissa Capital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":16390000,"source":{"system":"sec-edgar","filing":"0001567619-21-006050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000156761921006050/doc1.xml","form_type":"4"}},{"id":2796802,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-03-11T00:06:57.000Z","date":"2021-03-08","kind":"purchase","acquired":true,"shares":150000,"price":10.3,"value":1545000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of Sarissa Capital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":16315000,"source":{"system":"sec-edgar","filing":"0001567619-21-006050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000156761921006050/doc1.xml","form_type":"4"}},{"id":2805949,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-03-06T00:19:46.000Z","date":"2021-03-05","kind":"purchase","acquired":true,"shares":175000,"price":10.01,"value":1751750.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of Sarissa Capital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":16165000,"source":{"system":"sec-edgar","filing":"0001567619-21-005770","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000156761921005770/doc1.xml","form_type":"4"}},{"id":2805948,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-03-06T00:19:46.000Z","date":"2021-03-04","kind":"purchase","acquired":true,"shares":250000,"price":10,"value":2500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of Sarissa Capital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":15990000,"source":{"system":"sec-edgar","filing":"0001567619-21-005770","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000156761921005770/doc1.xml","form_type":"4"}},{"id":2805947,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-03-06T00:19:46.000Z","date":"2021-03-03","kind":"purchase","acquired":true,"shares":350000,"price":10.02,"value":3507000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of Sarissa Capital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":15740000,"source":{"system":"sec-edgar","filing":"0001567619-21-005770","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000156761921005770/doc1.xml","form_type":"4"}},{"id":2819852,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-03-03T01:18:07.000Z","date":"2021-03-02","kind":"purchase","acquired":true,"shares":500000,"price":9.56,"value":4780000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":15390000,"source":{"system":"sec-edgar","filing":"0001567619-21-005449","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000156761921005449/doc1.xml","form_type":"4"}},{"id":2819851,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-03-03T01:18:07.000Z","date":"2021-03-01","kind":"purchase","acquired":true,"shares":344900,"price":9.6,"value":3311040.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":14890000,"source":{"system":"sec-edgar","filing":"0001567619-21-005449","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000156761921005449/doc1.xml","form_type":"4"}},{"id":2819850,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-03-03T01:18:07.000Z","date":"2021-02-26","kind":"purchase","acquired":true,"shares":505100,"price":9.2,"value":4646920.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of shares that are held by Sarissa Capital Management LP (\"Sarissa Capital\") or by the funds and other investment vehicles (the \"Sarissa Funds\") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":14545100,"source":{"system":"sec-edgar","filing":"0001567619-21-005449","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000156761921005449/doc1.xml","form_type":"4"}},{"id":2863810,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142710,"kind":"organization","name":"Sarissa Capital Offshore Master Fund LP","position":3,"cik":"0001577530","reported_name":"Sarissa Capital Offshore Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142711,"kind":"organization","name":"Sarissa Capital Catapult Fund LLC","position":4,"cik":"0001716725","reported_name":"Sarissa Capital Catapult Fund LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142712,"kind":"organization","name":"Sarissa Capital Hawkeye Fund LP","position":5,"cik":"0001777184","reported_name":"Sarissa Capital Hawkeye Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142713,"kind":"organization","name":"Sarissa Capital Master Fund II LP","position":6,"cik":"0001811636","reported_name":"Sarissa Capital Master Fund II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.500% Exchangeable Senior Subordinated Note due 2025","published_at":"2021-02-12T20:22:13.000Z","date":"2021-02-11","kind":"exercise","acquired":false,"shares":15000000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the \"Reporting Persons\") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the \"Exchangeable Notes\"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the \"Reporting Persons\") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the \"Exchangeable Notes\"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership (\"Sarissa Offshore\"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company (\"Sarissa Catapult\") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership (\"Sarissa Hawkeye\") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv)  Sarissa Capital Master Fund II, a Delaware limited partnership (\"Sarissa Master II\" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the \"Sarissa Funds\") was the direct beneficial owner of 245,178 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the \"Reporting Persons\") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the \"Exchangeable Notes\"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership (\"Sarissa Offshore\"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company (\"Sarissa Catapult\") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership (\"Sarissa Hawkeye\") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv)  Sarissa Capital Master Fund II, a Delaware limited partnership (\"Sarissa Master II\" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the \"Sarissa Funds\") was the direct beneficial owner of 245,178 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Persons undertake to provide any securityholder of the Issuer, the Issuer or the SEC Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sarissa Capital Management LP, a Delaware limited partnership (\"Sarissa Capital\"), is the investment advisor to the Sarissa Funds and may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the Ordinary Shares.  Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer of Sarissa Capital and the ultimate general partner of Sarissa Capital, Sarissa Offshore, Sarissa Hawkeye, Sarissa Master II, and the managing member of Sarissa Catapult is controlled by Dr. Denner; accordingly, Dr. Denner may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Dr. Denner, Sarissa Capital, Sarissa Offshore, Sarissa Catapult, Sarissa Hawkeye and Sarissa Master II disclaims beneficial ownership of the Ordinary Shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_date":"2021-01-21","expiration_date":"2025-01-31","underlying":"Ordinary Shares","underlying_shares":20619949},"source":{"system":"sec-edgar","filing":"0000899243-21-006406","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1811636/000089924321006406/doc4.xml","form_type":"4"}},{"id":2863809,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142710,"kind":"organization","name":"Sarissa Capital Offshore Master Fund LP","position":3,"cik":"0001577530","reported_name":"Sarissa Capital Offshore Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142711,"kind":"organization","name":"Sarissa Capital Catapult Fund LLC","position":4,"cik":"0001716725","reported_name":"Sarissa Capital Catapult Fund LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142712,"kind":"organization","name":"Sarissa Capital Hawkeye Fund LP","position":5,"cik":"0001777184","reported_name":"Sarissa Capital Hawkeye Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142713,"kind":"organization","name":"Sarissa Capital Master Fund II LP","position":6,"cik":"0001811636","reported_name":"Sarissa Capital Master Fund II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2021-02-12T20:22:13.000Z","date":"2021-02-12","kind":"sale","acquired":false,"shares":10619949,"price":2.27,"value":24107284.23,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the \"Reporting Persons\") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the \"Exchangeable Notes\"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership (\"Sarissa Offshore\"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company (\"Sarissa Catapult\") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership (\"Sarissa Hawkeye\") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv)  Sarissa Capital Master Fund II, a Delaware limited partnership (\"Sarissa Master II\" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the \"Sarissa Funds\") was the direct beneficial owner of 245,178 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"On February 12, 2021, the Reporting Persons sold, in the aggregate 10,619,949 Ordinary Shares at a volume weighted average price of $2.27 per share. These shares were sold in multiple open market transactions at prices ranging from $2.24 to $2.27.  Of the aggregate amount of Ordinary Shares sold on February 12, 2021 by the Reporting Persons (i) Sarissa Offshore sold 6,245,491 Ordinary Shares, (ii) Sarissa Catapult sold 2,434,767 Ordinary Shares, (iii) Sarissa Hawkeye sold 1,813,213 Ordinary Shares and (iv) Sarissa Master II sold 126,478 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Persons undertake to provide any securityholder of the Issuer, the Issuer or the SEC Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sarissa Capital Management LP, a Delaware limited partnership (\"Sarissa Capital\"), is the investment advisor to the Sarissa Funds and may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the Ordinary Shares.  Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer of Sarissa Capital and the ultimate general partner of Sarissa Capital, Sarissa Offshore, Sarissa Hawkeye, Sarissa Master II, and the managing member of Sarissa Catapult is controlled by Dr. Denner; accordingly, Dr. Denner may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Dr. Denner, Sarissa Capital, Sarissa Offshore, Sarissa Catapult, Sarissa Hawkeye and Sarissa Master II disclaims beneficial ownership of the Ordinary Shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-006406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811636/000089924321006406/doc4.xml","form_type":"4"}},{"id":2863808,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142710,"kind":"organization","name":"Sarissa Capital Offshore Master Fund LP","position":3,"cik":"0001577530","reported_name":"Sarissa Capital Offshore Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142711,"kind":"organization","name":"Sarissa Capital Catapult Fund LLC","position":4,"cik":"0001716725","reported_name":"Sarissa Capital Catapult Fund LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142712,"kind":"organization","name":"Sarissa Capital Hawkeye Fund LP","position":5,"cik":"0001777184","reported_name":"Sarissa Capital Hawkeye Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142713,"kind":"organization","name":"Sarissa Capital Master Fund II LP","position":6,"cik":"0001811636","reported_name":"Sarissa Capital Master Fund II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2021-02-12T20:22:13.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":10000000,"price":2.59,"value":25900000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the \"Reporting Persons\") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the \"Exchangeable Notes\"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership (\"Sarissa Offshore\"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company (\"Sarissa Catapult\") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership (\"Sarissa Hawkeye\") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv)  Sarissa Capital Master Fund II, a Delaware limited partnership (\"Sarissa Master II\" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the \"Sarissa Funds\") was the direct beneficial owner of 245,178 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Following the exchange, on February 11, 2021, the Reporting Persons sold, in the aggregate, 10,000,000 Ordinary Shares at a volume weighted average price of $2.59 per share. These shares were sold in multiple open market transactions at prices ranging from $2.58 to $2.70.  Of the aggregate amount of Ordinary Shares sold on February 11, 2021 by the Reporting Persons (i) Sarissa Offshore sold 5,881,300 Ordinary Shares, (ii) Sarissa Catapult sold 2,292,700 Ordinary Shares, (iii) Sarissa Hawkeye sold 1,707,300 Ordinary Shares and (iv) Sarissa Master II sold 118,700 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Persons undertake to provide any securityholder of the Issuer, the Issuer or the SEC Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sarissa Capital Management LP, a Delaware limited partnership (\"Sarissa Capital\"), is the investment advisor to the Sarissa Funds and may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the Ordinary Shares.  Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer of Sarissa Capital and the ultimate general partner of Sarissa Capital, Sarissa Offshore, Sarissa Hawkeye, Sarissa Master II, and the managing member of Sarissa Catapult is controlled by Dr. Denner; accordingly, Dr. Denner may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Dr. Denner, Sarissa Capital, Sarissa Offshore, Sarissa Catapult, Sarissa Hawkeye and Sarissa Master II disclaims beneficial ownership of the Ordinary Shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":10619949,"source":{"system":"sec-edgar","filing":"0000899243-21-006406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811636/000089924321006406/doc4.xml","form_type":"4"}},{"id":2863807,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142710,"kind":"organization","name":"Sarissa Capital Offshore Master Fund LP","position":3,"cik":"0001577530","reported_name":"Sarissa Capital Offshore Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142711,"kind":"organization","name":"Sarissa Capital Catapult Fund LLC","position":4,"cik":"0001716725","reported_name":"Sarissa Capital Catapult Fund LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142712,"kind":"organization","name":"Sarissa Capital Hawkeye Fund LP","position":5,"cik":"0001777184","reported_name":"Sarissa Capital Hawkeye Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142713,"kind":"organization","name":"Sarissa Capital Master Fund II LP","position":6,"cik":"0001811636","reported_name":"Sarissa Capital Master Fund II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2021-02-12T20:22:13.000Z","date":"2021-02-11","kind":"exercise","acquired":true,"shares":20619949,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the \"Reporting Persons\") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the \"Exchangeable Notes\"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership (\"Sarissa Offshore\"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company (\"Sarissa Catapult\") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership (\"Sarissa Hawkeye\") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv)  Sarissa Capital Master Fund II, a Delaware limited partnership (\"Sarissa Master II\" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the \"Sarissa Funds\") was the direct beneficial owner of 245,178 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner, Sarissa Capital and the Sarissa Funds (each as defined below and, collectively, the \"Reporting Persons\") beneficially owned $15,00,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025 (the \"Exchangeable Notes\"), which became exchangeable into the Issuer's Ordinary Shares at the option of the holder on January 21, 2021. On February 11, 2021, all of the Exchangeable Notes held by the Reporting Persons (inclusive of accrued interest) were exchanged for 20,619,949 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(continued from footnote 1) As a result of the exchange (i) Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership (\"Sarissa Offshore\"), was the direct beneficial owner of 12,126,791, (ii) Sarissa Capital Catapult Fund LLC, a Delaware limited liability company (\"Sarissa Catapult\") was the direct beneficial owner of 4,727,467 Ordinary Shares, (iii) Sarissa Capital Hawkeye Fund LP, a Delaware limited partnership (\"Sarissa Hawkeye\") was the direct beneficial owner of 3,520,513 Ordinary Shares and (iv)  Sarissa Capital Master Fund II, a Delaware limited partnership (\"Sarissa Master II\" and, together with Sarissa Offshore, Sarissa Catapult, and Sarissa Hawkeye, the \"Sarissa Funds\") was the direct beneficial owner of 245,178 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Following the exchange, on February 11, 2021, the Reporting Persons sold, in the aggregate, 10,000,000 Ordinary Shares at a volume weighted average price of $2.59 per share. These shares were sold in multiple open market transactions at prices ranging from $2.58 to $2.70.  Of the aggregate amount of Ordinary Shares sold on February 11, 2021 by the Reporting Persons (i) Sarissa Offshore sold 5,881,300 Ordinary Shares, (ii) Sarissa Catapult sold 2,292,700 Ordinary Shares, (iii) Sarissa Hawkeye sold 1,707,300 Ordinary Shares and (iv) Sarissa Master II sold 118,700 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sarissa Capital Management LP, a Delaware limited partnership (\"Sarissa Capital\"), is the investment advisor to the Sarissa Funds and may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of the authority granted to it to vote and to dispose of the securities held by them, including the Ordinary Shares.  Alexander J. Denner, Ph.D., a citizen of the United States of America (\"Dr. Denner\"), is the Chief Investment Officer of Sarissa Capital and the ultimate general partner of Sarissa Capital, Sarissa Offshore, Sarissa Hawkeye, Sarissa Master II, and the managing member of Sarissa Catapult is controlled by Dr. Denner; accordingly, Dr. Denner may be deemed to have beneficial ownership over the Ordinary Shares directly beneficially owned by the Sarissa Funds by virtue of such positions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Dr. Denner, Sarissa Capital, Sarissa Offshore, Sarissa Catapult, Sarissa Hawkeye and Sarissa Master II disclaims beneficial ownership of the Ordinary Shares except, in each case, to the extent of their pecuniary interest therein."}],"balance_after":20616949,"source":{"system":"sec-edgar","filing":"0000899243-21-006406","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811636/000089924321006406/doc4.xml","form_type":"4"}},{"id":2939998,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2020-12-17T21:08:43.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issued pursuant to the Director Compensation Policy, effective May 2019."}],"balance_after":37844,"source":{"system":"sec-edgar","filing":"0001209191-20-064042","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120064042/doc4.xml","form_type":"4"}},{"id":2988198,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2020-11-09T21:07:55.000Z","date":"2020-11-09","kind":"grant","acquired":true,"shares":24925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in three equal installments on the first three anniversaries of the date of grant."}],"balance_after":37183,"source":{"system":"sec-edgar","filing":"0001209191-20-057438","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120057438/doc4.xml","form_type":"4"}},{"id":2988197,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2020-11-09T21:07:55.000Z","date":"2020-11-09","kind":"grant","acquired":true,"shares":12258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding\nthe date of the annual meeting of stockholders for the next calendar year."}],"balance_after":12258,"source":{"system":"sec-edgar","filing":"0001209191-20-057438","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120057438/doc4.xml","form_type":"4"}},{"id":2994357,"issuer":{"id":145567,"kind":"organization","name":"Sarissa Capital Acquisition Corp.","symbol":"SRSA"},"owners":[{"id":145568,"kind":"organization","name":"Sarissa Capital Acquisition Sponsor LLC","position":1,"cik":"0001821671","reported_name":"Sarissa Capital Acquisition Sponsor LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":3,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145569,"kind":"organization","name":"Sarissa Capital Management GP LLC","position":4,"cik":"0001577566","reported_name":"Sarissa Capital Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B ordinary shares","published_at":"2020-11-03T22:27:41.000Z","date":"2020-10-30","kind":"other","acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-249171) under the heading \"Description of Securities - Founder Shares,\" Class B ordinary shares of the issuer, par value $0.0001 per share (\"Class B Shares\"), will automatically convert into Class A ordinary shares of the issuer, par value $0.0001 per share (\"Class A Shares\"), at the time of the issuer's initial business combination, on a one-for-one basis, subject to certain adjustment, and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Forfeiture to the issuer for no consideration because the underwriter for the issuer's initial public offering did not fully exercise the over-allotment option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-249171) under the heading \"Description of Securities - Founder Shares,\" Class B ordinary shares of the issuer, par value $0.0001 per share (\"Class B Shares\"), will automatically convert into Class A ordinary shares of the issuer, par value $0.0001 per share (\"Class A Shares\"), at the time of the issuer's initial business combination, on a one-for-one basis, subject to certain adjustment, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-249171) under the heading \"Description of Securities - Founder Shares,\" Class B ordinary shares of the issuer, par value $0.0001 per share (\"Class B Shares\"), will automatically convert into Class A ordinary shares of the issuer, par value $0.0001 per share (\"Class A Shares\"), at the time of the issuer's initial business combination, on a one-for-one basis, subject to certain adjustment, and have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Sarissa Capital Management LP (the \"Managing Member\") is the managing member of Sarissa Capital Acquisition Sponsor LLC, the reporting person (the \"Sponsor\"), and as such, has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the ordinary shares held directly by the Sponsor. The general partner of the Managing Member is Sarissa Capital Management GP LLC, and the managing member of Sarissa Capital Management GP LLC is Alexander Denner. Alexander Denner also serves as the Chairman and Chief Executive Officer of the issuer.  Both Sarissa Capital Management GP LLC and Alexander Denner may be deemed to have shared beneficial ownership of the ordinary shares held directly by the Sponsor."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"(continued from footnote 3) Each of the issuer's officers and directors may hold a direct or indirect interest in the Sponsor. Each such person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly or indirectly."}],"balance_after":5000000,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0000899243-20-030264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1361754/000089924320030264/doc4.xml","form_type":"4"}},{"id":3000518,"issuer":{"id":145567,"kind":"organization","name":"Sarissa Capital Acquisition Corp.","symbol":"SRSA"},"owners":[{"id":145568,"kind":"organization","name":"Sarissa Capital Acquisition Sponsor LLC","position":1,"cik":"0001821671","reported_name":"Sarissa Capital Acquisition Sponsor LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":3,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145569,"kind":"organization","name":"Sarissa Capital Management GP LLC","position":4,"cik":"0001577566","reported_name":"Sarissa Capital Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase Class A ordinary shares","published_at":"2020-10-23T16:14:57.000Z","date":"2020-10-23","kind":"purchase","acquired":true,"shares":3333333,"price":1.5,"value":4999999.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sarissa Capital Acquisition Sponsor LLC (the \"Sponsor\") purchased 3,083,333 warrants, as described in the issuer's registration statement on Form S-1 (File No. 333-249171) (the \"S-1\"), in a private placement of warrants at a price of $1.50 per private placement warrant.  Each whole private placement warrant is exercisable to purchase one Class A ordinary share at a price of $11.50 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The warrants become exercisable on the later of (i) 30 days after the completion of the registrant's initial business combination and (ii) 12 months from the closing of the registrant's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the S-1."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The Sponsor is the reporting person.  Sarissa Capital Management LP (the \"Managing Member\") is the managing member of the Sponsor, and as such, has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the ordinary shares held directly by the Sponsor. The general partner of the Managing Member is Sarissa Capital Management GP LLC, and the managing member of Sarissa Capital Management GP LLC is Alexander Denner. Alexander Denner also serves as the Chairman and Chief Executive Officer of the issuer.  Both Sarissa Capital Management GP LLC and Alexander Denner may be deemed to have shared beneficial ownership of the ordinary shares held directly by the Sponsor. Each of the issuer's officers and directors may hold a direct or indirect interest in the Sponsor."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"(continued from footnote 4) Each such person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly or indirectly."}],"balance_after":3333333,"derivative":{"exercise_price":11.5,"underlying":"Class A ordinary shares","underlying_shares":3333333},"source":{"system":"sec-edgar","filing":"0000899243-20-029153","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1361754/000089924320029153/doc4.xml","form_type":"4"}},{"id":3121170,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-06-05T21:09:02.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":890,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12954,"source":{"system":"sec-edgar","filing":"0001127602-20-019014","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760220019014/form4.xml","form_type":"4"}},{"id":3319444,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-01-06T13:25:11.000Z","date":"2020-01-06","kind":"disposition_to_issuer","acquired":false,"shares":13410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":34.81,"underlying":"Common Stock","underlying_shares":13410},"source":{"system":"sec-edgar","filing":"0000950142-20-000042","document":"es2000127_4-denner.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000095014220000042/es2000127_4-denner.xml","form_type":"4"}},{"id":3319443,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-01-06T13:25:11.000Z","date":"2020-01-06","kind":"disposition_to_issuer","acquired":false,"shares":9141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":33.86,"underlying":"Common Stock","underlying_shares":9141},"source":{"system":"sec-edgar","filing":"0000950142-20-000042","document":"es2000127_4-denner.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000095014220000042/es2000127_4-denner.xml","form_type":"4"}},{"id":3319442,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-01-06T13:25:11.000Z","date":"2020-01-06","kind":"disposition_to_issuer","acquired":false,"shares":8577,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":39.39,"underlying":"Common Stock","underlying_shares":8577},"source":{"system":"sec-edgar","filing":"0000950142-20-000042","document":"es2000127_4-denner.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000095014220000042/es2000127_4-denner.xml","form_type":"4"}},{"id":3319441,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-01-06T13:25:11.000Z","date":"2020-01-06","kind":"disposition_to_issuer","acquired":false,"shares":9700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":37.22,"underlying":"Common Stock","underlying_shares":9700},"source":{"system":"sec-edgar","filing":"0000950142-20-000042","document":"es2000127_4-denner.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000095014220000042/es2000127_4-denner.xml","form_type":"4"}},{"id":3319440,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-01-06T13:25:11.000Z","date":"2020-01-06","kind":"disposition_to_issuer","acquired":false,"shares":27230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option (each an \"Option\") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":32.86,"underlying":"Common Stock","underlying_shares":27230},"source":{"system":"sec-edgar","filing":"0000950142-20-000042","document":"es2000127_4-denner.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000095014220000042/es2000127_4-denner.xml","form_type":"4"}},{"id":3319439,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-06T13:25:11.000Z","date":"2020-01-06","kind":"disposition_to_issuer","acquired":false,"shares":4202000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the \"Merger Agreement\"), by and among the Company, Novartis AG (\"Parent\") and Medusa Merger Corporation (\"Purchaser\"), on January 6, 2020, Purchaser was merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a \"Share\") was converted into the right to receive $85.00 per Share, net to the seller in cash (the \"Offer Price\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-20-000042","document":"es2000127_4-denner.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000095014220000042/es2000127_4-denner.xml","form_type":"4"}},{"id":3319438,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-06T13:25:11.000Z","date":"2020-01-06","kind":"disposition_to_issuer","acquired":false,"shares":85813,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the \"Merger Agreement\"), by and among the Company, Novartis AG (\"Parent\") and Medusa Merger Corporation (\"Purchaser\"), on January 6, 2020, Purchaser was merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a \"Share\") was converted into the right to receive $85.00 per Share, net to the seller in cash (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The number of Shares reported includes 3,663 unvested restricted Shares (each a \"Restricted Share\"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-20-000042","document":"es2000127_4-denner.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000095014220000042/es2000127_4-denner.xml","form_type":"4"}},{"id":3321933,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142710,"kind":"organization","name":"Sarissa Capital Offshore Master Fund LP","position":3,"cik":"0001577530","reported_name":"Sarissa Capital Offshore Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142711,"kind":"organization","name":"Sarissa Capital Catapult Fund LLC","position":4,"cik":"0001716725","reported_name":"Sarissa Capital Catapult Fund LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142712,"kind":"organization","name":"Sarissa Capital Hawkeye Fund LP","position":5,"cik":"0001777184","reported_name":"Sarissa Capital Hawkeye Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2020-01-04T02:53:43.000Z","date":"2019-12-24","kind":"purchase","acquired":true,"shares":4231620,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"See Exhibit 99.1."}],"balance_after":6083471,"derivative":{"exercise_price":6.66,"exercise_date":"2019-12-24","expiration_date":"2024-12-24","underlying":"Common Stock","underlying_shares":4231620},"source":{"system":"sec-edgar","filing":"0001567619-20-000438","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1361754/000156761920000438/doc1.xml","form_type":"4"}},{"id":3321932,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71303,"kind":"organization","name":"Sarissa Capital Management LP","position":2,"cik":"0001577524","reported_name":"Sarissa Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142710,"kind":"organization","name":"Sarissa Capital Offshore Master Fund LP","position":3,"cik":"0001577530","reported_name":"Sarissa Capital Offshore Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142711,"kind":"organization","name":"Sarissa Capital Catapult Fund LLC","position":4,"cik":"0001716725","reported_name":"Sarissa Capital Catapult Fund LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142712,"kind":"organization","name":"Sarissa Capital Hawkeye Fund LP","position":5,"cik":"0001777184","reported_name":"Sarissa Capital Hawkeye Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A-2 Convertible Preferred Stock","published_at":"2020-01-04T02:53:43.000Z","date":"2019-12-24","kind":"purchase","acquired":true,"shares":423162,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"See Exhibit 99.1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"See Exhibit 99.1."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"See Exhibit 99.1."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"See Exhibit 99.1."}],"balance_after":423162,"derivative":{"exercise_price":0.666,"underlying":"Common Stock","underlying_shares":4231620},"source":{"system":"sec-edgar","filing":"0001567619-20-000438","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1361754/000156761920000438/doc1.xml","form_type":"4"}},{"id":3476209,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-28T20:19:24.000Z","date":"2019-06-28","kind":"purchase","acquired":true,"shares":50000,"price":33,"value":1650000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":4202000,"source":{"system":"sec-edgar","filing":"0000950142-19-001465","document":"eh1900877_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000095014219001465/eh1900877_4.xml","form_type":"4"}},{"id":3483319,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-06-20T21:47:26.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":1155,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12064,"source":{"system":"sec-edgar","filing":"0001127602-19-022414","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219022414/form4.xml","form_type":"4"}},{"id":3505106,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2019-06-03T17:09:57.000Z","date":"2019-05-30","kind":"grant","acquired":true,"shares":13410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in one installment on May 30, 2020 and was made as part of and pursuant to Issuer's director compensation package."}],"balance_after":13410,"derivative":{"exercise_price":34.81,"expiration_date":"2029-05-30","underlying":"Common Stock","underlying_shares":13410},"source":{"system":"sec-edgar","filing":"0001179110-19-007024","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019007024/edgar.xml","form_type":"4"}},{"id":3505105,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T17:09:57.000Z","date":"2019-05-30","kind":"grant","acquired":true,"shares":3663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This restricted stock award vests on May 30, 2020 and was made as part of and pursuant to Issuer's director compensation package."}],"balance_after":14092,"source":{"system":"sec-edgar","filing":"0001179110-19-007024","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019007024/edgar.xml","form_type":"4"}},{"id":3506561,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T07:31:56.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":50000,"price":34.81,"value":1740500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":4152000,"source":{"system":"sec-edgar","filing":"0001179110-19-006871","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019006871/edgar.xml","form_type":"4"}},{"id":3506560,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T07:31:56.000Z","date":"2019-05-29","kind":"purchase","acquired":true,"shares":35000,"price":34.85,"value":1219750.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":4102000,"source":{"system":"sec-edgar","filing":"0001179110-19-006871","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019006871/edgar.xml","form_type":"4"}},{"id":3515595,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-22T17:56:14.000Z","date":"2019-05-22","kind":"purchase","acquired":true,"shares":139000,"price":33.13,"value":4605070.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":4067000,"source":{"system":"sec-edgar","filing":"0001179110-19-006513","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019006513/edgar.xml","form_type":"4"}},{"id":3515594,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-22T17:56:14.000Z","date":"2019-05-21","kind":"purchase","acquired":true,"shares":132000,"price":33.95,"value":4481400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":3928000,"source":{"system":"sec-edgar","filing":"0001179110-19-006513","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019006513/edgar.xml","form_type":"4"}},{"id":3515593,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-22T17:56:14.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":160000,"price":34.5,"value":5520000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":3796000,"source":{"system":"sec-edgar","filing":"0001179110-19-006513","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019006513/edgar.xml","form_type":"4"}},{"id":3543157,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-02T21:06:09.000Z","date":"2019-05-02","kind":"purchase","acquired":true,"shares":38000,"price":231.24,"value":8787120.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the \"Sarissa Funds\").  Alexander Denner is the Chief Investment Officer of Sarissa Capital and controls the ultimate general partner of the Sarissa Funds.  By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own."}],"balance_after":643000,"source":{"system":"sec-edgar","filing":"0001127602-19-017009","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219017009/form4.xml","form_type":"4"}},{"id":3543156,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-02T21:06:09.000Z","date":"2019-05-01","kind":"purchase","acquired":true,"shares":30000,"price":229.46,"value":6883800.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the \"Sarissa Funds\").  Alexander Denner is the Chief Investment Officer of Sarissa Capital and controls the ultimate general partner of the Sarissa Funds.  By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own."}],"balance_after":605000,"source":{"system":"sec-edgar","filing":"0001127602-19-017009","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219017009/form4.xml","form_type":"4"}},{"id":3543155,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-02T21:06:09.000Z","date":"2019-04-30","kind":"purchase","acquired":true,"shares":50342,"price":229.25,"value":11540903.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sarissa Capital Management LP (\"Sarissa Capital\") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the \"Sarissa Funds\").  Alexander Denner is the Chief Investment Officer of Sarissa Capital and controls the ultimate general partner of the Sarissa Funds.  By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own."}],"balance_after":575000,"source":{"system":"sec-edgar","filing":"0001127602-19-017009","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219017009/form4.xml","form_type":"4"}},{"id":3604528,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-08T13:13:35.000Z","date":"2019-03-06","kind":"purchase","acquired":true,"shares":248100,"price":24.91,"value":6180171.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares purchased ranging from a low of $24.84 to a high of $24.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":3636000,"source":{"system":"sec-edgar","filing":"0001179110-19-003591","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019003591/edgar.xml","form_type":"4"}},{"id":3614168,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-05T17:14:27.000Z","date":"2019-03-05","kind":"purchase","acquired":true,"shares":181900,"price":26.07,"value":4742133.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":3387900,"source":{"system":"sec-edgar","filing":"0001179110-19-003300","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019003300/edgar.xml","form_type":"4"}},{"id":3614167,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-05T17:14:27.000Z","date":"2019-03-04","kind":"purchase","acquired":true,"shares":325000,"price":25.45,"value":8271250.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares purchased ranging from a low of $25.40 to a high of $25.48 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":3206000,"source":{"system":"sec-edgar","filing":"0001179110-19-003300","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019003300/edgar.xml","form_type":"4"}},{"id":3614166,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-05T17:14:27.000Z","date":"2019-03-01","kind":"purchase","acquired":true,"shares":100000,"price":25.15,"value":2515000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares purchased ranging from a low of $25.11 to a high of $25.20 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed and/or controlled by Sarissa Capital Management LP. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and controls the general partner of Sarissa Capital Management LP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) these shares. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":2881000,"source":{"system":"sec-edgar","filing":"0001179110-19-003300","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911019003300/edgar.xml","form_type":"4"}},{"id":3680365,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-02-01T21:19:28.000Z","date":"2019-02-01","kind":"purchase","acquired":true,"shares":7000,"price":328.4518,"value":2299162.6,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sarissa Capital Management GP LLC, a Delaware limited liability company (\"Sarissa Capital GP\"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership (\"Sarissa Capital\"), the investment advisor to certain investment funds. Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that those funds directly beneficially own."}],"balance_after":524658,"source":{"system":"sec-edgar","filing":"0001127602-19-003363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219003363/form4.xml","form_type":"4"}},{"id":3680364,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-02-01T21:19:28.000Z","date":"2019-01-31","kind":"purchase","acquired":true,"shares":25800,"price":330.5191,"value":8527392.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sarissa Capital Management GP LLC, a Delaware limited liability company (\"Sarissa Capital GP\"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership (\"Sarissa Capital\"), the investment advisor to certain investment funds. Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that those funds directly beneficially own."}],"balance_after":517658,"source":{"system":"sec-edgar","filing":"0001127602-19-003363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219003363/form4.xml","form_type":"4"}},{"id":3680363,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-02-01T21:19:28.000Z","date":"2019-01-30","kind":"purchase","acquired":true,"shares":30000,"price":324.8617,"value":9745851.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sarissa Capital Management GP LLC, a Delaware limited liability company (\"Sarissa Capital GP\"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership (\"Sarissa Capital\"), the investment advisor to certain investment funds. Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that those funds directly beneficially own."}],"balance_after":491858,"source":{"system":"sec-edgar","filing":"0001127602-19-003363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219003363/form4.xml","form_type":"4"}},{"id":3722138,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-21T07:30:17.000Z","date":"2018-12-20","kind":"purchase","acquired":true,"shares":10000,"price":17.89,"value":178900.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"All of the shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed by Sarissa Capital Management LP (such funds, the \"Sarissa Funds\"). Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":2781000,"source":{"system":"sec-edgar","filing":"0001179110-18-014211","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911018014211/edgar.xml","form_type":"4"}},{"id":3727391,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"3.50% Convertible Senior Notes due 2024","published_at":"2018-12-18T16:16:07.000Z","date":"2018-12-18","kind":"purchase","acquired":true,"price":20000000,"reported_value":20000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Holders may convert the notes at any time prior to the close of business on the business day immediately preceding 10/15/23 only under the following circumstances: (1) during any calendar quarter commencing on or after 3/31/19 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the 5 business day period after any 5 consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On or after October 15, 2023, until the close of business on the business day immediately preceding the maturity date (i.e., until and including January 14, 2024), holders may convert their notes at any time, regardless of the foregoing circumstances."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"All of the shares and notes reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed by Sarissa Capital Management LP (such funds, the \"Sarissa Funds\"). Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares and notes that the Sarissa Funds directly beneficially own.  Dr. Denner disclaims beneficial ownership of these shares and notes except to the extent of his pecuniary interest therein."}],"derivative":{"exercise_price":25.19,"exercise_date":"2023-10-15","expiration_date":"2024-01-14","underlying":"Common Stock","underlying_shares":793840},"source":{"system":"sec-edgar","filing":"0001179110-18-014054","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911018014054/edgar.xml","form_type":"4"}},{"id":3727390,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-18T16:16:07.000Z","date":"2018-12-18","kind":"purchase","acquired":true,"shares":10000,"price":18.18,"value":181800.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"All of the shares and notes reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed by Sarissa Capital Management LP (such funds, the \"Sarissa Funds\"). Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares and notes that the Sarissa Funds directly beneficially own.  Dr. Denner disclaims beneficial ownership of these shares and notes except to the extent of his pecuniary interest therein."}],"balance_after":2771000,"source":{"system":"sec-edgar","filing":"0001179110-18-014054","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911018014054/edgar.xml","form_type":"4"}},{"id":3727389,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-18T16:16:07.000Z","date":"2018-12-17","kind":"purchase","acquired":true,"shares":20000,"price":17.91,"value":358200.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"All of the shares and notes reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed by Sarissa Capital Management LP (such funds, the \"Sarissa Funds\"). Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares and notes that the Sarissa Funds directly beneficially own.  Dr. Denner disclaims beneficial ownership of these shares and notes except to the extent of his pecuniary interest therein."}],"balance_after":2761000,"source":{"system":"sec-edgar","filing":"0001179110-18-014054","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911018014054/edgar.xml","form_type":"4"}},{"id":3729670,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-17T16:21:49.000Z","date":"2018-12-14","kind":"purchase","acquired":true,"shares":219000,"price":18.97,"value":4154430.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares purchased ranging from a low of $18.94 to a high of $19.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed by Sarissa Capital Management LP (such funds, the \"Sarissa Funds\"). Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":2741000,"source":{"system":"sec-edgar","filing":"0001179110-18-013924","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911018013924/edgar.xml","form_type":"4"}},{"id":3729669,"issuer":{"id":152552,"kind":"organization","name":"MEDICINES CO /DE","symbol":"MDCO"},"owners":[{"id":37234,"kind":"person","name":"DENNER ALEXANDER J","position":1,"cik":"0001361754","reported_name":"DENNER ALEXANDER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-17T16:21:49.000Z","date":"2018-12-13","kind":"purchase","acquired":true,"shares":600000,"price":20.73,"value":12438000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares purchased ranging from a low of $19.86 to a high of $21.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by funds managed by Sarissa Capital Management LP (such funds, the \"Sarissa Funds\"). Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":2522000,"source":{"system":"sec-edgar","filing":"0001179110-18-013924","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113481/000117911018013924/edgar.xml","form_type":"4"}}],"next_cursor":"2018-12-17T16:21:49.000000Z,3729669"}